First phase study

The second part of our 1st phase study has just been successfully completed with no Serious Adverse Events.

Drug administration was performed on ECU, where Subjects were provided with carefull medical care. As a standard, Team of Specialists (Anesthesiologist, Psychiatrist, two Investigators and Nurses) was present during the procedure just to assure maximum safety and quality of recorded data. Vital signs of the Subjects were constantly monitored (BP holter and ECG monitoring) and assessed by a Physician.

Go back

News

Comprehensive Patient Care in BRG Clinical Trials

 At BRG, comprehensive patient care is not an addition — it is the standard.

Read more …

BRG Conducts a Study on Nicotine Concentrations in New Tobacco-Free HNB Products

BioResearch Group (BRG) is conducting a medical experiment aimed at assessing nicotine concentrations following the use of new tobacco-free heated non-burning (HNB) products

Read more …

Clinical research reshapes nicotine regulation - BRG article in ITJ

upcoming publication by Dr. Katarzyna Jarus-Dziedzic, on the increasing importance of clinical studies in the Tobacco Market

Read more …

Data Quality at the Center of Regulatory Attention – the BRG Standard

In recent months, regulators have placed an even stronger emphasis on data quality in clinical trials.

Read more …

Regulatory change across the European Union

Flavoured heated tobacco (HnB) sticks withdrawn from sale as of 18 January 2025

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2026 © Bio Research Group. All rights reserved.

 

scroll to top ▲